

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Novo Nordisk A/S	09/28/2012
RECEIVING PARTY DATA	
Name:	TransTech Pharma, Inc.
Street Address:	4170 Mendenhall Oaks Parkway
City:	High Point
State/Country:	NORTH CAROLINA
Postal Code:	27265
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	8138185
CORRESPONDENCE DATA	
Fax Number:	6099875440
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	609-987-5800
Email:	nnipatent@novonordisk.com
Correspondent Name:	Novo Nordisk Inc.
Address Line 1:	100 College Road West
Address Line 4:	Princeton, NEW JERSEY 08540
ATTORNEY DOCKET NUMBER:	7562.204-US
NAME OF SUBMITTER:	Karen Schlauch
Total Attachments: 3 source=TTPAssignment#page1.tif source=TTPAssignment#page2.tif source=TTPAssignment#page3.tif	

CH \$40.00 8138185

ASSIGNMENT

WHEREAS: NOVO NORDISK A/S, a corporation organized under the laws of Denmark, having an address of Novo Allé, DK-2880 Bagsværd, Denmark (hereinafter ASSIGNOR), is an owner of the patent(s) and/or application(s) set forth on Exhibit A hereto and the inventions described and claimed therein (hereafter the "Patent Property"); and

WHEREAS: TRANSTECH PHARMA, INC., a corporation organized under the laws of Delaware, U.S. having an address of 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265, U.S. (hereinafter ASSIGNEE), desires to acquire from ASSIGNOR, ASSIGNOR'S entire right, title and interest in and to the Patent Property.


NOW, THEREFORE, for good and valuable consideration provided by ASSIGNEE to ASSIGNOR, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR does hereby sell, assign and transfer to ASSIGNEE, its successors, legal representatives, or assigns, ASSIGNOR'S full and exclusive rights, titles and interests in and to said Patent Property, as well as all priority applications, provisional applications, continuing applications, division applications, continuation-in-part applications of said Patent Property, and all reissues, reexaminations, and extensions thereof, the same to be held and enjoyed by ASSIGNEE for its own use and benefit, and for the benefit of its successors, assigns, or legal representatives, to the end of the term or terms for which such Patent Property may be granted or reissued, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR if this assignment and sale had not been made.

ASSIGNOR also assigns to ASSIGNEE, all right, title and interest in and to the inventions disclosed in said Patent Property throughout the world, including the right to file applications and obtain patents, utility models, industrial models and designs for said Patent Property in its own name throughout the world, including all rights to publish cautionary notices reserving ownership of said inventions and all rights to register said Patent Property in appropriate registries.

IN WITNESS THEREOF, the parties have caused this Patent Assignment to be executed on the date and in the capacity shown below.

NOVO NORDISK A/S

By:



Mads Krogsgaard Thomsen
Chief Science Officer
Novo Nordisk A/S


Name:

LSN/S

Title:

Date:

20 SEP 2012



LSN/S

Jesper Brandgaard
Chief Financial Officer
Novo Nordisk A/S

20 SEP 2012

EXHIBIT A

Patent Property

(Schedule of Patents/Patent Applications)

Novo Nordisk Reference	U.S. Patent Application Number	U.S. Patent Number
6937.204-US	11/791,200	8,148,412
6937.214-US	13/022,937	Pending
7208.204-US	11/994,718	7,999,114
7209.204-US	11/994,728	7,582,769
7562.204-US	12/522,286	8,138,185